FR16C0016I1 - - Google Patents

Info

Publication number
FR16C0016I1
FR16C0016I1 FR16C0016C FR16C0016I1 FR 16C0016 I1 FR16C0016 I1 FR 16C0016I1 FR 16C0016 C FR16C0016 C FR 16C0016C FR 16C0016 I1 FR16C0016 I1 FR 16C0016I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR16C0016I1 publication Critical patent/FR16C0016I1/fr
Application granted granted Critical
Publication of FR16C0016I2 publication Critical patent/FR16C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fish Paste Products (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
FR16C0016C 2000-03-10 2016-04-29 Facteur viii modifie Active FR16C0016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/523,656 US6458563B1 (en) 1996-06-26 2000-03-10 Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en) 2000-03-10 2001-02-16 Modified factor viii

Publications (2)

Publication Number Publication Date
FR16C0016I1 true FR16C0016I1 (de) 2016-04-29
FR16C0016I2 FR16C0016I2 (fr) 2018-11-02

Family

ID=24085870

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0016C Active FR16C0016I2 (fr) 2000-03-10 2016-04-29 Facteur viii modifie

Country Status (36)

Country Link
US (3) US6458563B1 (de)
EP (1) EP1280540B1 (de)
JP (1) JP4044337B2 (de)
KR (1) KR100485525B1 (de)
CN (1) CN1191360C (de)
AT (1) ATE391512T1 (de)
AU (2) AU2001238416B2 (de)
BE (1) BE2016C024I2 (de)
BR (2) BR122013026957A8 (de)
CA (1) CA2400295C (de)
CY (2) CY1108179T1 (de)
CZ (1) CZ298250B6 (de)
DE (1) DE60133541T2 (de)
DK (1) DK1280540T3 (de)
EE (1) EE05075B1 (de)
ES (1) ES2304379T3 (de)
FR (1) FR16C0016I2 (de)
HK (1) HK1051004A1 (de)
HU (2) HU227804B1 (de)
IL (2) IL151371A0 (de)
LT (1) LTC1280540I2 (de)
LU (1) LU93049I2 (de)
ME (1) ME00601B (de)
MX (1) MXPA02008798A (de)
NL (1) NL300808I2 (de)
NO (2) NO331935B1 (de)
NZ (1) NZ520799A (de)
PL (1) PL202936B1 (de)
PT (1) PT1280540E (de)
RS (1) RS50364B (de)
RU (1) RU2285724C2 (de)
SI (1) SI1280540T1 (de)
SK (1) SK286205B6 (de)
UA (1) UA75064C2 (de)
WO (1) WO2001068109A1 (de)
ZA (1) ZA200206810B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US7615622B2 (en) * 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1572889B1 (de) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
EP1636360A4 (de) * 2003-06-03 2006-11-08 Cell Genesys Inc Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle
ATE368687T1 (de) * 2003-06-26 2007-08-15 Merck Patent Gmbh Thrombopoietinproteine mit verbesserten eigenschaften
US20050059023A1 (en) * 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
AU2004296768B2 (en) * 2003-12-03 2010-06-24 University Of Rochester Recombinant factor VIII having increased specific activity
DK1750733T3 (da) * 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
WO2005123928A1 (en) * 2004-06-08 2005-12-29 Battelle Memorial Institute Production of human coagulation factor viii from plant cells and whole plants
HUE033776T2 (en) * 2004-11-12 2018-01-29 Bayer Healthcare Llc FVIII site-specific modification
US20100256062A1 (en) 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090215025A1 (en) 2005-12-07 2009-08-27 Technische Universitat Munchen Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US20100222554A1 (en) * 2006-04-11 2010-09-02 Thomas Weimer Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (de) * 2006-12-22 2008-06-25 CSL Behring GmbH Veränderte Koagulationsfaktoren mit verlängerter in vivo Halbwertzeit
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (de) 2007-05-04 2008-11-05 Novo Nordisk A/S Verbesserung von Faktor-VIII-Polypeptid-Titern in Zellkulturen
AU2008319183B2 (en) 2007-11-01 2014-09-04 University Of Rochester Recombinant factor VIII having increased stability
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
PL2440239T3 (pl) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Kompozycje hemoglobiny
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011060372A2 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
US9050318B2 (en) 2009-12-06 2015-06-09 Biogen Idec Hemophilia Inc. Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011088391A2 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
KR20140036144A (ko) * 2011-01-05 2014-03-25 익스프레션 테라퍼틱스 엘엘씨 고수율 현탁세포주, 시스템 및 그 제조방법
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
WO2013009627A2 (en) 2011-07-08 2013-01-17 Biogen Idec Hemophilia Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CN102277379B (zh) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 表达凝血因子viii的表达载体及其应用
PT2802668T (pt) 2012-01-12 2018-12-04 Puget Sound Blood Center Processos para reduzir a imunogenicidade contra o fator viii em indivíduos a receber terapêutica com fator viii
SG11201403764XA (en) 2012-01-12 2014-07-30 Biogen Idec Inc Chimeric factor viii polypeptides and uses thereof
EP3549953A1 (de) 2012-02-15 2019-10-09 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
EP2814840B1 (de) 2012-02-15 2019-11-13 Bioverativ Therapeutics Inc. Faktor-viii-zusammensetzungen und verfahren zur herstellung und verwendung davon
EP2666782A1 (de) * 2012-05-22 2013-11-27 Imnate Sarl Gerinnungsfaktor VII mit reduzierter Immunogenität
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
EP2863940A4 (de) 2012-06-08 2016-08-10 Biogen Ma Inc Chimäre gerinnungsfaktoren
EP2870250B2 (de) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
EP3674410A1 (de) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc. Faktor-viii-komplex mit xten und von-willebrand-faktor-protein sowie verwendungen davon
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
BR112015013311A2 (pt) 2012-12-07 2017-11-14 Haplomics Inc indução de tolerancia e reparação de mutação do fator 8
DK3889173T3 (da) 2013-02-15 2023-10-09 Bioverativ Therapeutics Inc Optimeret faktor viii-gen
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
SG11201509313PA (en) 2013-06-28 2016-01-28 Biogen Ma Inc Thrombin cleavable linker with xten and its uses thereof
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015059121A1 (en) 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
KR102409250B1 (ko) 2014-01-10 2022-06-14 바이오버라티브 테라퓨틱스 인크. 인자 viii 키메라 단백질 및 이들의 용도
EP3102589A1 (de) 2014-02-04 2016-12-14 Biogen MA Inc. Verwendung von kationenaustauscherchromatographie im durchflussmodus zur anreicherung von posttranslationalen modifikationen
US20170051041A1 (en) * 2014-02-19 2017-02-23 Kathleen Pratt Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (de) 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
PE20231949A1 (es) * 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
AU2016353353B2 (en) 2015-11-13 2020-07-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
CN108602876B (zh) 2015-11-13 2022-07-05 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
JP2020519272A (ja) * 2017-05-09 2020-07-02 エモリー ユニバーシティー 凝固因子変異体及びその使用
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
KR20200118089A (ko) 2018-02-01 2020-10-14 바이오버라티브 테라퓨틱스 인크. 인자 viii을 발현하는 렌티바이러스 벡터의 용도
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
CN112449640A (zh) 2018-07-16 2021-03-05 百深公司 使用编码具有增加的表达的重组fviii变体的病毒载体的a型血友病的基因疗法
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
EP3986481A2 (de) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Verfahren zur behandlung mit einer auf viren basierenden gentherapie
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202246505A (zh) * 2021-03-05 2022-12-01 俄羅斯聯邦商亞那拜恩有限公司 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
WO2022212162A1 (en) * 2021-03-31 2022-10-06 Haemonetics Corporation Hemostasis measurement device quality control formulations
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
AU2022355088A1 (en) 2021-09-30 2024-05-16 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (de) 1984-08-24 1987-10-28 Genetics Institute, Inc. Verfahren zur Herstellung von Faktor VIII und verwandte Produkte
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU6291896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
JP2004525608A (ja) * 2000-09-19 2004-08-26 エモリー ユニバーシテイ 修飾された因子ｖｉｉｉ
AU2002364509A1 (en) * 2001-11-30 2003-06-17 Emory University Factor viii c2 domain variants
US7105745B2 (en) * 2002-12-31 2006-09-12 Thomas & Betts International, Inc. Water resistant electrical floor box cover assembly

Also Published As

Publication number Publication date
LU93049I2 (fr) 2016-06-27
NO20024296L (no) 2002-11-08
HU227804B1 (en) 2012-03-28
NO331935B1 (no) 2012-05-07
WO2001068109A1 (en) 2001-09-20
MXPA02008798A (es) 2003-04-25
IL151371A (en) 2010-12-30
ATE391512T1 (de) 2008-04-15
HUS1600020I1 (hu) 2016-06-28
EE200200510A (et) 2004-02-16
CA2400295C (en) 2012-01-10
RS50364B (sr) 2009-11-10
PT1280540E (pt) 2008-06-09
EE05075B1 (et) 2008-10-15
KR20020081426A (ko) 2002-10-26
AU2001238416B2 (en) 2004-09-02
BR122013026957A8 (pt) 2017-02-21
CY1108179T1 (el) 2014-02-12
NL300808I2 (nl) 2020-12-21
EP1280540A1 (de) 2003-02-05
YU68002A (sh) 2005-11-28
SI1280540T1 (sl) 2008-08-31
US20030068785A1 (en) 2003-04-10
PL202936B1 (pl) 2009-08-31
JP4044337B2 (ja) 2008-02-06
EP1280540A4 (de) 2004-11-03
AU3841601A (en) 2001-09-24
US20050079584A1 (en) 2005-04-14
ZA200206810B (en) 2003-11-26
BRPI0109131B1 (pt) 2020-08-25
IL151371A0 (en) 2003-04-10
UA75064C2 (en) 2006-03-15
HUP0300586A3 (en) 2006-11-28
ES2304379T3 (es) 2008-10-16
CA2400295A1 (en) 2001-09-20
BR0109131A (pt) 2004-12-07
CY2016011I2 (el) 2016-10-05
US6458563B1 (en) 2002-10-01
US7122634B2 (en) 2006-10-17
DK1280540T3 (da) 2008-07-14
NO2016007I2 (no) 2016-05-10
DE60133541T2 (de) 2009-05-07
NO20024296D0 (no) 2002-09-09
RU2285724C2 (ru) 2006-10-20
NL300808I1 (de) 2016-05-18
BE2016C024I2 (de) 2020-01-30
MEP8209A (en) 2011-12-20
CY2016011I1 (el) 2016-10-05
US7012132B2 (en) 2006-03-14
NO2016007I1 (no) 2016-05-10
SK286205B6 (sk) 2008-05-06
CZ298250B6 (cs) 2007-08-01
PL359672A1 (en) 2004-09-06
SK14392002A3 (sk) 2003-06-03
BRPI0109131B8 (pt) 2021-07-06
KR100485525B1 (ko) 2005-04-28
FR16C0016I2 (fr) 2018-11-02
RU2002124123A (ru) 2004-03-27
HUP0300586A2 (hu) 2003-06-28
BR122013026957A2 (de) 2004-12-07
NZ520799A (en) 2004-06-25
CN1191360C (zh) 2005-03-02
CN1416348A (zh) 2003-05-07
DE60133541D1 (de) 2008-05-21
JP2003526358A (ja) 2003-09-09
HK1051004A1 (en) 2003-07-18
LTC1280540I2 (lt) 2020-05-25
CZ20023346A3 (cs) 2003-01-15
ME00601B (me) 2011-12-20
EP1280540B1 (de) 2008-04-09

Similar Documents

Publication Publication Date Title
FR16C0016I1 (de)
JP2001216766A5 (de)
JP2003513544A5 (de)
BRPI0110940B8 (de)
AR028236A3 (de)
AU2000236813A8 (de)
BE2014C025I2 (de)
JP2003519584A5 (de)
JP2003508812A5 (de)
IN2002CH01637A (de)
JP2002055124A5 (de)
CH694022C1 (de)
JP2002137806A5 (de)
JP2002090606A5 (de)
JP2003518646A5 (de)
BRPI0000763B8 (de)
CN3139997S (de)
CN3136721S (de)
CN3145095S (de)
CN3144928S (de)
CN3143422S (de)
CN3142149S (de)
CN3141409S (de)
CN3141398S (de)
CN3149068S (de)